drugset / Trial / NCT00317486

Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology

NCT00317486

Phase 4 Completed 54 enrolled Actelion
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluates the effects of bosentan on oxygen saturation, hemodynamics and exercise capacity in patients with pulmonary arterial hypertension related to Eisenmenger physiology. Patients receive bosentan or placebo for 16 weeks.

Timeline

Start
2003-09
Primary completion
2005-04
Completion
2005-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosentan Other / unclassified

Indications